Corvus Pharmaceuticals (CRVS) slipped 1.4%. In company news, Babylon Holdings (BBLN) was falling 5.1%, reversing an early 3.6% gain that followed the digital health care company Friday raising its FY22 revenue forecast to a new range of $900 million to $1 billion, reflecting more than $80 million in revenue during January and the company signing new care agreements expected to add around 88,000 new members. The biopharmaceutical company late Thursday said Chinese partner Angel Pharmaceuticals doses the first patient in a phase I/Ib trial of its CPI-818 drug candidate in patients with a variety of relapsed/refractory T-cell lymphomas.